The current study looked at treatment data from 2 randomized trials conducted by the Women’s Health Initiative with long term follow up. The effects of MHT on incidence and mortality from ovarian ...

A new study finds that GLP-1 medications are linked to lower overall cancer risk, particularly for endometrial and ovarian ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Analysis of data from over 1.2 million US patients with gynecologic cancers between 2004 and 2020 revealed a significant shift towards surgical de-escalation, with increased use of minimally invasive ...

During a trip to France in the 2000s, Carolyn Taylor remembers feeling depressed, unusual for her, especially on vacation. She also noticed she was bleeding between her periods, so she contacted her ...

April 29, 2009 — A weekly regimen of topotecan and docetaxel for recurrent uterine and ovarian cancers in heavily pretreated women might provide clinicians with another option in this difficult ...

A gynaecologist explains how certain lifestyle habits and hormonal changes may increase endometrial cancer risk, and the early symptoms of this cancer type.

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal ...

What Is Metastatic Endometrial Cancer? Metastatic endometrial cancer is when cancer that starts in the lining of the uterus (endometrium) spreads to other parts of the body. Your doctor may call it ...

Uterine cancer symptoms include irregular bleeding and pelvic pain, but early diagnosis through medical evaluation can lead ...

The potential benefits of GLP-1 medications continue to expand. New research has found that the weight loss and diabetes drugs — officially known as glucagon-like peptide 1 receptor agonists — are ...